Video summary

Future of Infectious Diseases in Respiratory and Critical Care / CRCCID recorded Module - 25

Main summary

Key takeaways

Educational

Summary

The module first recaps management of drug-resistant tuberculosis (TB), then looks ahead at infectious-disease diagnostics and antimicrobial treatment in critical care.

1. Drug-resistant TB: diagnosis and treatment principles

  • Identify drug resistance promptly. Molecular tests such as Xpert/NAAT are used early to detect Mycobacterium tuberculosis and rifampicin resistance. Further molecular testing, culture, and drug-susceptibility testing (DST) help establish resistance to other drugs and guide treatment.
  • Key resistance categories:
    • Rifampicin-resistant TB (RR-TB): Rifampicin resistance detected.
    • Multidrug-resistant TB (MDR-TB): Resistance to at least isoniazid and rifampicin.
    • Pre-XDR-TB: MDR/RR-TB plus fluoroquinolone resistance.
    • XDR-TB: MDR/RR-TB plus fluoroquinolone resistance and resistance to a Group A drug, such as bedaquiline or linezolid.
    • Isoniazid-resistant, rifampicin-susceptible TB follows a separate treatment pathway.
  • Do not add a single drug to a failing regimen. Failure to improve should prompt reassessment of adherence, dosing, absorption, interactions, disease progression, and culture/DST results. Adding one drug to a failing regimen can amount to functional monotherapy and select for further resistance.
  • Assess disease site and severity before choosing a regimen. Extensive pulmonary disease and severe extrapulmonary disease—especially TB meningitis or CNS, spinal, skeletal, or disseminated disease—may not be suitable for shorter regimens. Complex cases should be discussed with a drug-resistant TB centre.

2. Regimen selection and monitoring for drug-resistant TB

  • BPaLM—bedaquiline, pretomanid, linezolid, and moxifloxacin—was described as the preferred shorter, all-oral regimen for eligible patients aged 14 years and older. The usual course is 26 weeks, with possible extension to 39 weeks in specified circumstances.
    • Before starting, assess prior exposure or resistance to regimen drugs, pregnancy or breastfeeding, disease severity, QT interval, blood counts, liver function, and other relevant clinical risks.
    • According to the speaker, fluoroquinolone resistance does not automatically rule out BPaLM. Eligibility and regimen choice still require expert review.
    • Linezolid toxicity is a major concern. If significant toxicity occurs early, the regimen may need to be considered unsuccessful and replaced with an appropriate longer regimen. Later toxicity may permit dose reduction, with treatment extension and close monitoring.
    • If moxifloxacin cannot be tolerated, the speaker described dropping it and extending the remaining regimen in selected cases. Resistance to a core drug or substantial treatment interruption requires reassessment rather than simply restarting or switching drugs.
  • The 9–11-month shorter oral regimen is an alternative for selected patients who cannot receive BPaLM. Fluoroquinolone resistance, extensive pulmonary disease, and severe extrapulmonary disease are key reasons it may be unsuitable. The updated programme regimen described in the talk replaces ethionamide with linezolid in the intensive phase.
  • Longer individualized oral regimens, roughly 18–20 months, may be needed when shorter regimens are unsuitable, resistance emerges, drugs cannot be tolerated, or treatment fails. The regimen should be built using drugs expected to be active based on DST, with expert guidance. Avoid weakening it by removing a drug without replacing it with an effective option.
  • Isoniazid-resistant, rifampicin-susceptible TB follows a distinct regimen. If the patient deteriorates or develops evidence of rifampicin resistance, reassess for MDR/RR-TB rather than continuing the same pathway without review.

Baseline assessment and follow-up emphasized in the lecture:

  • Review prior TB and second-line drug exposure, adherence risks, substance use, weight and height, comorbidities, neurological symptoms, vision, and current medications.
  • Obtain baseline blood tests and investigations as appropriate, including CBC and platelets, kidney function and electrolytes, liver function, blood glucose, HIV status, pregnancy testing when relevant, chest X-ray, and ECG. Screen for peripheral neuropathy and document visual acuity and colour vision.
  • Counsel patients about adherence, expected adverse effects, possible drug interactions, and symptoms requiring same-day review. Examples include visual changes, tingling or weakness, fainting or palpitations, jaundice, vomiting, bleeding, or rash. Separate antacids or supplements from fluoroquinolones when relevant.
  • Monitor weight, BMI, adherence, and adverse effects at regular visits. The speaker described serial ECG and CBC monitoring, eye checks during treatment, monthly sputum smear and culture from the second month, and repeat DST when cultures remain positive or the patient worsens. Imaging and liver tests should also be repeated at specified points.
  • Continue follow-up after treatment completion. For interruptions beyond the stated limits, or persistent positivity or treatment failure, repeat the assessment and consult the relevant TB centre rather than blindly restarting the regimen.

3. Future diagnostics for infection and sepsis

Professor Marvin Singer focused on the need to answer three questions quickly: Is there an infection? What is causing it? Which treatment is likely to work?

  • Conventional culture is slow and can miss infections. Results often take days, and blood cultures are positive in only a minority of suspected cases. Prior antibiotics and organisms that are difficult to grow can further reduce yield.
  • Molecular tests can identify pathogens faster. Panels may detect bacteria, fungi, viruses, and selected resistance genes, but they are incomplete. A resistance gene does not always establish that a drug will fail, and a negative panel does not rule out resistance mechanisms it does not test for.
  • Metagenomic sequencing is a promising broader approach. It can detect genetic material from multiple organisms, and some studies described in the talk returned results within hours. Results sometimes changed antimicrobial prescribing. The speaker also noted a key limitation: detecting an organism’s DNA does not by itself prove that it is alive or causing disease.
  • Combining pathogen and host information may improve interpretation. Metagenomic approaches can potentially assess both microbial material and the patient’s immune-response signature, helping distinguish likely infection from incidental detection or sterile inflammation. This remains an evolving approach.
  • Rapid phenotypic susceptibility testing aims to show directly whether an antibiotic inhibits the organism, sometimes in hours rather than waiting for conventional susceptibility results. The speaker presented this as a promising area that still requires validation and broader adoption.
  • Host-response tests and biomarkers, including inflammatory markers and gene-expression signatures, may help estimate the likelihood of bacterial or viral infection. They are not sufficiently specific to use alone: trauma, surgery, burns, and other non-infectious conditions can also affect them.
  • Practical barriers remain. Cost, staffing, laboratory capacity, and access to tests limit routine use. Clinical assessment and reassessment over time remain essential, particularly when test results are uncertain.

4. Antimicrobial treatment and stewardship

Dr. Andrew discussed the balance between effective early treatment and avoiding unnecessary antimicrobial exposure.

  • Antimicrobials can harm the individual patient as well as drive population resistance. Potential harms include drug toxicity and allergy, selection of resistant organisms within the patient, and disruption of the microbiome.
  • Use existing drugs optimally before relying on newer ones. Select treatment according to the likely infection and resistance pattern, and account for the patient’s changing drug handling in critical illness. Dose, tissue penetration, and pharmacokinetics matter.
  • Prolonged beta-lactam infusions may improve treatment in some settings. The speaker reviewed evidence suggesting potential gains in clinical cure and outcomes, while noting that trial results and effect sizes require interpretation.
  • Newer agents often target particular resistance mechanisms. The talk reviewed beta-lactam/beta-lactamase inhibitor combinations and other drugs intended to address resistant Gram-negative organisms. The practical principle is to match a drug to the resistance mechanism it can cover, rather than using reserve agents indiscriminately. Resistance can still emerge.
  • Other approaches remain experimental. These include bacteriophages, CRISPR-modified phages, new antibiotic classes, AI-designed molecules, monoclonal antibodies, and iron-sequestering therapies. The speaker emphasized that these approaches face substantial efficacy, safety, manufacturing, and regulatory challenges.
  • Build stewardship into clinical practice:
    • Take cultures before antibiotics when the patient’s condition allows; do not delay urgent treatment in a critically ill patient.
    • Use local prescribing guidance based on local resistance patterns.
    • Avoid antibiotics for likely viral illness or sterile inflammation.
    • Review treatment every day as clinical and laboratory information becomes available.
    • Narrow the spectrum or stop treatment when evidence supports doing so.
    • Do not extend courses automatically when the patient has improved.
    • Treat stewardship as a team effort involving clinicians, pharmacists, and microbiologists.

5. Discussion and closing points

In the Q&A, the speakers said that rapid diagnostics combining pathogen detection with host-response information could be especially useful, but cost and availability remain major obstacles. They also stressed that careful clinical review, experience, and a culture in which it is acceptable to observe selected patients without immediate antibiotics are important in both well-resourced and resource-limited settings.

The speakers argued that antimicrobial resistance is not inevitable: reducing unnecessary use can lessen selective pressure, and coordinated attention from clinicians, health systems, and governments can help. The module concluded with thanks to the faculty, participants, organizers, and supporting organizations.

Speakers and sources featured

  • Dr. Kamcha/Kanga Chawla — recap lecturer on drug-resistant TB; the captions render her name inconsistently.
  • Dr. Rajesh Mishra — session chair/moderator.
  • Dr. Tagu/Singh — co-chair; the captions render the name inconsistently.
  • Professor Marvin Singer — presentation on future infection and sepsis diagnostics.
  • Dr. Andrew — presentation on future therapeutics and antimicrobial strategies; the captions do not provide a consistently clear full name.
  • Dr. Aditi Mishra — medical advisor for Z Biosciences; delivered sponsor remarks.
  • Opening and closing remarks: A course organizer identified in the captions as “Dr. Challa,” but the exact name is unclear.
  • Organizations acknowledged: National College of Chest Physicians India, Indian Society of Critical Care Medicine, and Z Biosciences.

Rate this summary

Your feedback will help improve summaries.

Improve this summary

Reprocess with a stronger model when the summary feels incomplete or inaccurate.

Pro

Translate summary in another language

Pro

Ask questions to this video

Chat for follow-up questions, clarifications, and source-backed answers.

Coming soon

Share this summary

Original video